https://10kdoank.wonhundred.com/products/slot-depo-10k

https://10kaja.wonhundred.com/products/slot-depo-10k

https://10kmurah.artwareeditions.com/products/slot-10k

https://nxsengine.artwareeditions.com/products/nexus-engine-slot

https://enginenxs.enamelpinfactory.com/products/nexus-slot

https://slotnxs.enamelpinfactory.com/products/nexus-slot

https://100doank.wonhundred.com/products/slot-bet-100

https://100gacor.wonhundred.com/products/slot-bet-100

https://100tong.crankbrothers.com/products/link-slot-bet-100

https://bonustong.crankbrothers.com/products/slot-bonus-100

https://bonusgacor.wonhundred.com/products/link-slot-bonus-100

https://bonusom.wonhundred.com/products/bonus-slot-100

https://rtpcakep.beziergames.com/products/rtp-slot

https://rtpgg.beziergames.com/products/rtp-slot-live

https://rtpgacor.wonhundred.com/products/rtp-slot-info

Business

Ferrari, Apple, KB Home and more




Signs are posted in front of homes under construction at a KB Home housing development on January 12, 2022 in Novato, California.

Justin Sullivan | Getty Images

Take a look at the companies making the biggest moves in premarket trading:

Ferrari — Shares of the luxury automaker rose less than 1% early Monday after Morgan Stanley analyst Adam Jonas named it a top pick, replacing Tesla. In a note to clients, Jonas cited Ferrari’s backlog and price strength as reasons for raising the price target on the stock by more than 10%.

apple — The iPhone maker advanced 2% premarket after Goldman Sachs initiated coverage with a buy rating, saying Apple could get a big boost from its services business. The Wall Street bank’s 12-month price target of $199 suggests Apple could rise more than 30% from here.

KB Home — The homebuilder fell 1.4% after a double downgrade to underweight from overweight by JPMorgan. The firm cited the stock’s expensive valuation.

DR Horton — DR Horton, another homebuilder, fell a little more than 1% after it was downgraded by JPMorgan to neutral from overweight. Analysts said the stock’s premium valuation fairly reflected its above-average fundamental profile and expect the stock to perform only in line with its peers.

Vir Biotechnology — The biotech rose 5% after JPMorgan upgraded it to overweight from neutral. The bank said Vir has long-term pipeline opportunities across a range of disease indications.

Silvergate capital — The bank continued its decline and fell around 8% pre-market. Last week, Silvergate Capital warned about its ability to continue as a going concern and delayed the filing of its annual report.

— CNBC’s Yun Li and Jesse Pound contributed reporting.



Source link

Back to top button